delta 9-tetrahydrocannabinol in clinical oncology.

“After anecdotal reports of marijuana’s providing antiemetic activity in cancer chemotherapy patients refractory to standard agents, orally administereddelta 9-tetrahydrocannabinol (THC) was formally studied by a number of investigators.

In six of seven well-controlled studies, orally administered THC was a superior antiemetic agent compared with control agents.

Overall, the benefits of orally administered THC use represent a major advance in antiemetic therapy.”

http://www.ncbi.nlm.nih.gov/pubmed/6262541

http://www.thctotalhealthcare.com/category/cancer/

Leave a Reply

Your email address will not be published. Required fields are marked *